Lv3
210 积分 2026-03-20 加入
Decoding EGFR A289 Mutation in Glioblastoma: A Predictive Biomarker Framework and Targeted Therapeutic Insights
24天前
已完结
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations
25天前
已完结
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma
1个月前
已完结
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
1个月前
已完结
皖公网安备34019202002308
